List of Excipients in Branded Drug Farxiga

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	FARXIGA	dapagliflozin	0310-6205	ANHYDROUS LACTOSE
AstraZeneca Pharmaceuticals LP	FARXIGA	dapagliflozin	0310-6205	CELLULOSE, MICROCRYSTALLINE
AstraZeneca Pharmaceuticals LP	FARXIGA	dapagliflozin	0310-6205	CROSPOVIDONE
AstraZeneca Pharmaceuticals LP	FARXIGA	dapagliflozin	0310-6205	MAGNESIUM STEARATE
AstraZeneca Pharmaceuticals LP	FARXIGA	dapagliflozin	0310-6205	SILICON DIOXIDE
A-S Medication Solutions	FARXIGA	dapagliflozin	50090-3481	ANHYDROUS LACTOSE
A-S Medication Solutions	FARXIGA	dapagliflozin	50090-3481	CELLULOSE, MICROCRYSTALLINE

FARXIGA Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Patent Analysis

Last updated: September 27, 2026

FARXIGA (dapagliflozin propanediol) uses a conventional immediate-release, film-coated tablet platform built around microcrystalline cellulose, anhydrous lactose, crospovidone, colloidal silicon dioxide, magnesium stearate, and a polyvinyl alcohol-based coating system. The formulation is commercially attractive because it relies on widely available excipients, does not require modified release, and supports low-cost generic manufacture. The principal opportunities are in excipient substitution, direct-compression optimization, taste-masked oral products, fixed-dose combinations, pediatric formulations, and regional supply contracts.

Farxiga’s commercial value is driven by its use in type 2 diabetes, heart failure, and chronic kidney disease. AstraZeneca reported approximately $7 billion in Farxiga sales in 2024, making dapagliflozin one of the largest global SGLT2 inhibitor products.[1] Generic entry risk is concentrated in conventional tablets and is distinct from opportunities for differentiated formulations that may qualify for separate regulatory or patent protection.

What excipients are used in FARXIGA tablets?

The FDA prescribing information identifies the following inactive ingredients for Farxiga tablets:[2]

Formulation component	Listed excipient or material	Primary function
Tablet core	Microcrystalline cellulose	Diluent, compressibility, tablet structure
Tablet core	Anhydrous lactose	Diluent and filler
Tablet core	Crospovidone	Superdisintegrant
Tablet core	Colloidal silicon dioxide	Glidant and moisture-flow aid
Tablet core	Magnesium stearate	Lubricant
Film coating	Polyvinyl alcohol	Film-forming polymer
Film coating	Titanium dioxide	Opacifier and pigment
Film coating	Polyethylene glycol	Plasticizer
Film coating	Talc	Anti-tacking and coating aid
Film coating	Yellow iron oxide	Colorant

Farxiga is supplied as 5-mg and 10-mg film-coated tablets. The product is an immediate-release oral dosage form. Its excipient system is consistent with high-volume tablet manufacturing and does not depend on a proprietary delivery platform, sustained-release matrix, lipid system, or enteric coating.

What is the role of dapagliflozin propanediol?

The active pharmaceutical ingredient is dapagliflozin propanediol, a crystalline form of dapagliflozin used to support solid-state stability and pharmaceutical processing. The salt or solvate form is separate from the inactive excipient system and can affect particle properties, dissolution, hygroscopicity, and tablet content uniformity.

A generic developer must control:

• Polymorphic or solvate form;
• Water content;
• Particle-size distribution;
• Bulk and tapped density;
• Flow and segregation;
• Blend uniformity;
• Dissolution across relevant pH conditions;
• Stability under accelerated and long-term storage.

The active form, rather than an excipient alone, is likely to be the more material component of solid-state and pharmaceutical-development risk.

How does the FARXIGA formulation support generic development?

The reference product has a relatively low-complexity formulation profile. A generic manufacturer can generally pursue a conventional abbreviated new drug application using an immediate-release tablet with the same active ingredient and comparable dissolution and bioequivalence performance.

A practical generic formulation strategy would retain the functional roles of the reference excipients while evaluating alternative grades or suppliers:

Development objective	Reference approach	Potential generic alternative
Dilution and tablet strength	Microcrystalline cellulose plus anhydrous lactose	Spray-dried lactose, mannitol, dibasic calcium phosphate, silicified MCC
Disintegration	Crospovidone	Croscarmellose sodium or sodium starch glycolate
Flow	Colloidal silicon dioxide	Alternative high-dispersibility silica grades
Lubrication	Magnesium stearate	Sodium stearyl fumarate or optimized magnesium stearate grade
Film formation	Polyvinyl alcohol	Hypromellose or comparable immediate-release coating polymer
Plasticization	Polyethylene glycol	Alternative PEG grade or compatible plasticizer
Color	Iron oxide and titanium dioxide	Equivalent permitted color system

Substitution is not automatically risk-free. Excipients can alter tablet porosity, wetting, disintegration, dissolution, hardness, friability, and impurity formation. Crospovidone grade and particle morphology can be especially important in low-dose tablets because the drug load is small relative to the total tablet mass.

What excipient attributes are most important for FARXIGA?

Low-dose content uniformity

Dapagliflozin tablets contain 5 mg or 10 mg of active ingredient. The formulation therefore requires reliable dilution and blending. Direct compression can reduce processing steps, but it increases sensitivity to segregation and powder-flow differences.

Commercially relevant controls include:

• Narrow active-particle-size distribution;
• Geometric dilution or ordered blending;
• Low-segregation excipient combinations;
• Consistent bulk density;
• Blend sampling plans that detect stratification;
• Robust tablet-weight control.

Co-processed excipients can create an opportunity if they improve flow and reduce segregation without changing the dissolution profile. A supplier that offers a validated direct-compression platform for low-dose drugs could compete for generic dapagliflozin supply contracts.

Disintegration and dissolution

Crospovidone, lactose, microcrystalline cellulose, and tablet porosity collectively determine water uptake and breakup. Excessive compression force or over-lubrication can slow dissolution. A generic product must demonstrate adequate dissolution similarity against the reference product and meet applicable pharmacopeial specifications.

The strongest excipient opportunity is not simply replacing crospovidone. It is developing a formulation that maintains rapid release across changes in compression force, tablet hardness, and manufacturing scale.

Moisture and stability

Anhydrous lactose, polyvinyl alcohol coating systems, and the active solid form each require moisture-control assessment. The formulation developer should evaluate:

• Water activity;
• Lactose-related degradation pathways;
• Dapagliflozin assay and impurity growth;
• Packaging interaction;
• Film-coat moisture transfer;
• Stability after bottle opening;
• Blister versus high-density polyethylene bottle performance.

Desiccant-compatible packaging and low-moisture excipient grades may create a commercial advantage in tropical and high-humidity markets.

What formulations are protected by FARXIGA-related patents?

The relevant patent estate has historically included claims directed to dapagliflozin compounds, pharmaceutical compositions, crystalline or solid forms, and therapeutic uses. The core compound protection has expired or approached expiration in the United States, while later patents and regulatory exclusivities have affected the timing and scope of generic entry.

The principal formulation risk areas are:

Patent subject	Generic relevance	Excipient exposure
Dapagliflozin compound claims	Broad active-ingredient barrier	Low direct excipient relevance
Dapagliflozin propanediol or solid-state claims	Controls API form and manufacture	May require a specific solid form
Pharmaceutical composition claims	May cover tablets or dosage ranges	Can affect excipient selection if claim language is narrow
Method-of-treatment claims	Relevant to labeled indications	Usually does not prevent all-purpose tablet manufacture
Fixed-dose combination claims	Relevant to combination products	May cover excipient and dose architecture
Pediatric or special-population claims	May affect label carve-outs	May create differentiated product opportunities

Excipient identity alone usually does not create strong protection unless the patent claims a specific composition, ratio, dissolution profile, particle-size range, manufacturing process, or stability result. A generic developer should review the complete Orange Book listing, issued patents, terminal disclaimers, pediatric extensions, and any litigation settlement terms before selecting a launch date.

What is the Orange Book status of FARXIGA?

Farxiga is an FDA-approved small-molecule drug listed in the Orange Book under dapagliflozin propanediol. The Orange Book identifies reference-listed-drug information and patent certifications relevant to abbreviated new drug applications.[3]

The commercial implications are:

1. Conventional dapagliflozin tablets are the primary generic target.
2. A Paragraph IV certification may challenge listed patents before their stated expiration.
3. A Paragraph III certification can support a later launch after patent expiry.
4. A Section viii statement may allow approval for non-patented uses through labeling restrictions.
5. Pediatric exclusivity or other regulatory extensions can shift the effective launch date.

Orange Book listings must be checked against the current FDA database because patent listings, delistings, expiration dates, and certifications can change. A patent’s presence in the Orange Book does not independently establish infringement or validity.

When does FARXIGA lose exclusivity?

Farxiga’s market exclusivity depends on several separate dates:

Exclusivity category	Commercial effect
New chemical entity exclusivity	Prevents ANDA submission for a defined period
Patent protection	Can delay approval or launch if valid and enforceable
Pediatric exclusivity	Can extend qualifying patent or exclusivity periods by six months
Orphan-drug exclusivity	Relevant only to qualifying indications
Regulatory exclusivity for new indications	May protect specific labeling claims without blocking all generic sales
Settlement-based launch date	May permit entry before patent expiration under agreed terms

The core small-molecule and initial product protections do not provide indefinite exclusivity. Generic entry is most likely to begin with standard 5-mg and 10-mg immediate-release tablets, while differentiated combinations, pediatric products, and new delivery systems may have separate regulatory positions.

A precise launch-date assessment requires reconciliation of the current Orange Book, FDA approval letters, patent expiry calculations, and any confidential or public settlement terms. The operative date should not be inferred from a single patent number.

Which companies are challenging FARXIGA patents?

Dapagliflozin has attracted generic competition because it is a high-revenue oral medicine with a conventional tablet presentation. Generic applicants may include large multinational manufacturers, Indian pharmaceutical companies, and specialty generic firms with established diabetes portfolios.

The relevant competitive groups include:

• Companies filing ANDAs for dapagliflozin tablets;
• Manufacturers pursuing dapagliflozin and metformin combinations;
• Firms targeting non-U.S. markets after local patent expiry;
• Suppliers developing alternative dapagliflozin solid forms;
• Contract development and manufacturing organizations supporting low-cost launches.

Paragraph IV litigation, if filed, may involve compound, solid-state, formulation, or method-of-use patents. Settlement agreements can divide the market by launch date, dosage form, indication, or authorized-generic rights. A generic settlement does not necessarily eliminate competition; it often defines the timing and commercial structure of entry.

What litigation status affects FARXIGA generic entry?

The litigation analysis should separate four questions:

Is the patent listed for the reference product?

Only patents listed for the relevant reference product create the standard Orange Book certification framework. Unlisted patents can still support infringement claims, but they do not operate identically within the ANDA process.

Does the ANDA require a Paragraph IV certification?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. Notice to the patent holder can trigger litigation and a statutory stay of approval, subject to the Hatch-Waxman framework.[4]

Is the patent tied to all uses or only one indication?

Method-of-use patents may be addressed through a Section viii statement or labeling carve-out. A generic product may enter for unprotected indications while omitting a patented use, depending on FDA labeling requirements and litigation risk.

Does the settlement authorize an agreed launch?

A settlement may define an authorized launch date and may grant rights to sell under specified conditions. The agreement may also cover supply, royalties, manufacturing sources, or restrictions on authorized-generic competition.

How strong is the FARXIGA patent estate?

The estate is strongest where claims cover the active compound or a commercially necessary solid form. It is weaker where claims cover a narrow excipient ratio, a single manufacturing parameter, or a specific therapeutic indication that can be omitted from generic labeling.

Patent layer	Relative strength	Why
Core dapagliflozin compound	High historically, declining after expiry	Broad product coverage but finite term
Specific solid form or propanediol form	Medium to high	Can constrain API sourcing and solid-state selection
Conventional tablet composition	Medium	Depends on claim breadth and design-around options
Method of use	Medium	Strength depends on indication and labeling strategy
Narrow excipient combination	Low to medium	Often design-aroundable unless tied to performance limitations
New delivery system	Potentially high	Can support separate patent and regulatory value

For excipient suppliers, the key point is that a generic manufacturer can usually avoid a narrow formulation patent by changing excipient grades, ratios, coating polymers, or process conditions, provided bioequivalence and stability remain acceptable.

What commercial opportunities exist for FARXIGA excipients?

Direct generic-tablet supply

The largest near-term opportunity is supplying high-volume excipients for standard dapagliflozin tablets. Competitive advantages include:

• Regulatory documentation in major markets;
• Multiple qualified manufacturing sites;
• Low extractables and leachables risk;
• Consistent particle-size distribution;
• Strong supply continuity;
• Technical support for scale-up;
• DMF or equivalent supporting documentation where useful.

MCC, lactose, crospovidone, silica, magnesium stearate, coating polymers, pigments, and plasticizers are all established product categories. Price competition will be intense, so reliability and formulation support are more defensible than commodity pricing alone.

Co-processed excipient systems

A co-processed filler-disintegrant or filler-glidant platform could reduce segregation and improve direct compression. The value proposition is strongest for low-dose tablets manufactured at high speed.

Potential performance claims include:

• Lower tablet-weight variability;
• Better blend uniformity;
• Faster disintegration;
• Reduced sensitivity to compression force;
• Lower lubricant sensitivity;
• Improved scale-up consistency.

Such products may be protected by composition and process patents if the performance is difficult to reproduce with routine excipient substitution.

Pediatric and swallowability products

Dapagliflozin has pediatric and adolescent use in specific regulatory contexts. Orally disintegrating tablets, mini-tablets, granules, and dispersible tablets could address swallowing and dose-flexibility needs.

Commercial development must manage:

• Pediatric excipient acceptability;
• Palatability;
• Dose uniformity;
• Reconstitution or dispersion;
• Stability after opening;
• Age-appropriate packaging;
• Regulatory requirements for inactive ingredients.

A taste-masked formulation may create a stronger product position than a conventional tablet, but it also increases development cost and excipient qualification requirements.

Fixed-dose combinations

Dapagliflozin is commercially relevant in combinations with metformin and other cardiometabolic therapies. Combination tablets can reduce pill burden and support adherence, but they introduce compatibility and dissolution challenges.

Excipient opportunities include:

• Bilayer tablet platforms;
• Multiparticulate systems;
• Low-moisture formulations;
• Separate dissolution environments within one dosage form;
• High-load direct-compression systems;
• Film coatings that distinguish strengths and products.

Combination products may have their own patents, regulatory exclusivities, and labeling requirements. The excipient strategy should be developed around the complete active-ingredient combination rather than dapagliflozin alone.

How does FARXIGA compare with competing SGLT2 inhibitors?

Product	Active ingredient	Typical oral form	Excipient opportunity
Farxiga	Dapagliflozin	Immediate-release film-coated tablet	High-volume generic tablet and combination supply
Jardiance	Empagliflozin	Immediate-release film-coated tablet	Similar excipient and coating opportunity
Invokana	Canagliflozin	Immediate-release tablet	Generic solid-dose development
Steglatro	Ertugliflozin	Immediate-release tablet	Smaller market, potentially lower scale
Combination products	Dapagliflozin or other SGLT2 inhibitor plus a second active	Multi-component tablet	Greater formulation complexity and differentiation

Farxiga has a broad indication profile spanning diabetes, heart failure, and kidney disease. That increases commercial demand but also makes method-of-use patent analysis and label management more important than for a product with one principal indication.

What geographic opportunities exist for FARXIGA excipient suppliers?

The United States and European Union offer the largest value pools but also impose demanding qualification and documentation standards. India, China, Latin America, and Southeast Asia offer volume opportunities as local generic markets expand.

Region	Main opportunity	Main constraint
United States	ANDA generic supply and authorized-generic manufacturing	Orange Book, litigation, supplier qualification
European Union	Decentralized and national generic markets	Country-specific launch and reimbursement dynamics
India	API, excipient, and finished-dose manufacturing	Price pressure and local competition
China	Domestic generic and chronic-disease supply	Local approval and procurement pricing
Latin America	Finished-dose and excipient distribution	Market-by-market registration
Southeast Asia	Regional generic expansion	Import registration and supply-chain qualification

Manufacturing-related intellectual property is more relevant to API solid form and process control than to ordinary tablet excipients. Suppliers should maintain separate freedom-to-operate reviews for dapagliflozin API, finished-dose formulation, and coating technology.

What generic launch scenarios exist for FARXIGA?

Early authorized or settlement-based entry

A settlement may allow a selected generic or authorized generic to enter before the last listed patent expiry. This scenario can compress margins and reduce the value of exclusive excipient supply agreements.

Multiple-generic launch

If several ANDAs become approvable at the same time, tablet excipient demand may rise sharply while finished-dose pricing declines. Suppliers with dual-source capability and validated alternate grades are better positioned.

Carve-out launch

A generic may launch with patented indications removed from labeling. This creates a need for careful promotional controls and may preserve part of the reference product’s protected market.

Differentiated formulation launch

A pediatric, orally disintegrating, dispersible, or fixed-dose product may launch under a separate regulatory strategy. These products can support higher margins but face greater formulation and clinical development risk.

Key Takeaways

• Farxiga uses a conventional immediate-release tablet with microcrystalline cellulose, anhydrous lactose, crospovidone, colloidal silicon dioxide, magnesium stearate, and a polyvinyl alcohol-based film coat.
• The formulation is well suited to generic development and large-scale direct compression.
• The highest-volume excipient opportunity is standard generic dapagliflozin tablets and dapagliflozin/metformin combinations.
• Co-processed excipients can create value by improving low-dose content uniformity, flow, and compression robustness.
• Pediatric, orally disintegrating, dispersible, and taste-masked products offer higher differentiation than a standard tablet.
• Solid-state and active-ingredient patents are generally more important than ordinary excipient patents.
• Method-of-use patents can affect labeling and launch strategy even when they do not block every generic indication.
• Commercial planning should integrate the current Orange Book, patent litigation, settlement terms, regulatory exclusivity, and regional launch rules.
• Farxiga’s high global revenue base supports substantial excipient demand, but generic entry will create strong price pressure on commodity materials.

FAQs

Can a generic FARXIGA tablet use different excipients?

Yes. A generic manufacturer can generally use different inactive ingredients if the product meets FDA requirements for pharmaceutical quality, bioequivalence, dissolution, stability, and labeling. Excipient changes must not create a clinically meaningful difference or undermine product performance.

Is lactose necessary in dapagliflozin tablets?

No. Lactose is used in the reference formulation, but a generic developer may evaluate other diluents such as mannitol, spray-dried lactose, silicified microcrystalline cellulose, or dibasic calcium phosphate. The replacement must support acceptable compression, dissolution, stability, and patient tolerability.

Are excipient patents a major barrier to dapagliflozin generics?

Usually not for conventional tablets. The more material barriers are active-ingredient solid form, listed formulation claims, method-of-use patents, regulatory exclusivity, and litigation settlements. A narrow excipient claim can often be designed around unless it covers a necessary performance profile.

What is the best excipient opportunity after generic FARXIGA entry?

The strongest opportunity is a validated low-dose direct-compression platform that improves blend uniformity, tablet robustness, and dissolution while reducing manufacturing variability. Standard commodity excipients will face greater price competition.

Can an orally disintegrating dapagliflozin product obtain separate protection?

Potentially. A novel orally disintegrating or taste-masked product may support formulation patents, regulatory differentiation, or a separate product strategy if it demonstrates a meaningful technical or clinical advantage. Protection depends on the claims, regulatory pathway, and market-specific patent rules.

References

1. AstraZeneca PLC. (2025). Annual report and Form 20-F for the year ended December 31, 2024. AstraZeneca.

2. U.S. Food and Drug Administration. (2024). Farxiga (dapagliflozin) prescribing information. AstraZeneca Pharmaceuticals LP.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.